Ionis receives FDA approval for Tryngolza to treat severe hypertriglyceridemia.

Ionis Pharmaceuticals announced the FDA approval of olezarsen (Tryngolza), a new treatment for severe hypertriglyceridemia. This marks the company's first independent commercial launch in a prevalent disease and is designed to significantly reduce acute pancreatitis risk in patients.